Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1634-7800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.89 billion
Profitability
Miscellaneous
Employees1,360
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings data on Tuesday, August, 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.16 by $0.49. The specialty pharmaceutical company earned $534.13 million during the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the business earned $3.49 EPS. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $14.30-15.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.81. The company issued revenue guidance of $2.07-2.15 billion, compared to the consensus revenue estimate of $2.09 billion.
What price target have analysts set for JAZZ?
14 brokers have issued 1 year price objectives for Jazz Pharmaceuticals' shares. Their predictions range from $135.00 to $208.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $175.3846 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.
What is the consensus analysts' recommendation for Jazz Pharmaceuticals?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth." (8/8/2019)
- 2. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, witnessed improved volume trends in 2018 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients is likely to boost Jazz’s top line. Management seems confident that Xyrem will continue to generate volume growth in 2019. Meanwhile, Jazz’s lead pipeline candidate, solriamfetol complements the sleep disorder portfolio and successful development will offset decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, also witnessed strong growth in late 2018. Launch in Europe will also boost sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity. These supply challenges are expected to continue in 2019. Los estimates have been stable ahead of the company’s Q1 earnings release. The company has a positive record of earnings surprises in the recent quarters." (5/6/2019)
- 3. Mizuho analysts commented, "We raise our PT to $147 from $137 based on two recent positive catalysts: approval of Sunosi (solriamfetol for excessive sleepiness), and last night’s positive data in the Phase III trial of JZP-258 (low sodium Xyrem). Both these events were largely expected and we reiterate our Neutral rating on JAZZ." (3/27/2019)
- 4. Cantor Fitzgerald analysts commented, "We have an Overweight rating and a 12-month price target of $185 on JAZZ shares. We believe that the sleep franchise durability remains underappreciated and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts in 2019 and upward earnings revisions in both segments of the business will drive upside to JAZZ’s current share price. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $185 price target." (3/26/2019)
Has Jazz Pharmaceuticals been receiving favorable news coverage?
News articles about JAZZ stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Jazz Pharmaceuticals.
Are investors shorting Jazz Pharmaceuticals?
Jazz Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totalling 2,596,500 shares, an increase of 14.8% from the June 30th total of 2,262,200 shares. Based on an average daily volume of 470,900 shares, the days-to-cover ratio is presently 5.5 days. Currently, 4.7% of the shares of the company are sold short. View Jazz Pharmaceuticals' Current Options Chain.
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Mylan (MYL) and Sarepta Therapeutics (SRPT).
What other stocks do shareholders of Jazz Pharmaceuticals own?
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
- Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
- Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58)
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.72%), BlackRock Inc. (7.19%), Renaissance Technologies LLC (4.51%), JPMorgan Chase & Co. (3.98%), Nuveen Asset Management LLC (3.40%) and Putnam Investments LLC (2.17%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which institutional investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Bank of New York Mellon Corp, Scout Investments Inc., Vanguard Group Inc., Amundi Pioneer Asset Management Inc., First Trust Advisors LP, Carillon Tower Advisers Inc. and UBS Group AG. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which institutional investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, AQR Capital Management LLC, Smith Asset Management Group LP, LSV Asset Management, Schroder Investment Management Group, Parametric Portfolio Associates LLC and Seizert Capital Partners LLC. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $136.90.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $7.75 billion and generates $1.89 billion in revenue each year. The specialty pharmaceutical company earns $447.10 million in net income (profit) each year or $12.24 on an earnings per share basis. Jazz Pharmaceuticals employs 1,360 workers across the globe.View Additional Information About Jazz Pharmaceuticals.
What is Jazz Pharmaceuticals' official website?
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
